drugset / Trial / NCT03294798
Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the dosages of recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects. The secondary purposes is to get the PK/PD data in recombinant human serum albumin/interferon alpha2b fusion protein injection on HBV subjects.
Timeline
- Start
- 2017-06-13
- Primary completion
- 2019-03-15
- Completion
- 2021-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human Serum Albumin/interferon alpha2b fusion protein | Protein / enzyme biologic | 600 ug | — |
| Subject | Human Serum Albumin/interferon alpha2b fusion protein | Protein / enzyme biologic | 750 ug | — |
| Subject | Human Serum Albumin/interferon alpha2b fusion protein | Protein / enzyme biologic | 900 ug | — |
| Comparator | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |